文献速递帕金森病与运动障碍

CVT-301吸入性左旋多巴治疗帕金森病关期的3期试验

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
PubMed 文献 · Lancet Neurol · 2019-01-01

这项随机、双盲、安慰剂对照3期试验纳入351例帕金森病患者,评估CVT-301(左旋多巴吸入粉)治疗关期运动症状的安全性和疗效。

要点

  • CVT-301 84 mg可显著改善帕金森病关期UPDRS运动评分。
  • 严重不良事件发生率低,安全耐受性良好。

核心结论

  • CVT-301可改善帕金森病患者在临床关期的UPDRS运动评分,且严重或重度不良事件较少。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,在加拿大、波兰、西班牙和美国的65个中心招募患者。
  • 纳入30-85岁、每日关期≥2小时、口服左旋多巴加多巴脱羧酶抑制剂后UPDRS运动评分改善≥25%的帕金森病患者。
  • 351例患者按1:1:1随机分配至CVT-301 60 mg组(115例)、84 mg组(120例)或安慰剂组(116例)。
  • 主要终点为第12周临床关期时给药前至给药后30分钟UPDRS运动评分变化,比较84 mg组与安慰剂组,采用意向性分析。

主要发现

  • 重度不良事件:安慰剂组2/112(2%),60 mg组7/113(6%),84 mg组5/114(4%),任何治疗组中无同一重度不良事件发生于超过1例患者。
  • 严重不良事件:339例中11例(3%)发生19起(安慰剂组3/112[3%],60 mg组6/113[5%],84 mg组2/114[2%]),其中低血压和房颤被研究者评估为可能与研究药物相关。

临床怎么用

  • CVT-301 84 mg可作为帕金森病患者关期的按需治疗选择,需进一步研究长期安全性和疗效。

局限性

  • 长期安全性和疗效需在未来研究中进一步探讨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with Parkinson's disease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients with Parkinson's disease during off periods. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial, patients were recruited at 65 sites in Canada, Poland, Spain, and the USA. Eligible participants were patients with Parkinson's disease aged 30-85 years, who had daily off periods of 2 h or longer and showed an improvement of 25% or greater in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score from off to on state after use of an oral levodopa plus a dopa-decarboxylase inhibitor combination. Patients were assigned (1:1:1) with a computer-generated randomisation code, in fixed blocks of six, to either CVT-301 60 mg, CVT-301 84 mg, or placebo. Spirometry results and modified Hoehn and Yahr disease stage at screening were used for stratification of treatment groups. Patients, the sponsor, and site personnel were masked to treatment assignment. Each study dose consisted of two capsules administered with an inhaler. Patients were instructed to use the study drug as needed for off periods, and could self-administer up to five doses per day. The primary endpoint was the change in UPDRS motor score from predose to 30 min postdose, assessed at week 12 during an in-clinic off period, in the CVT-301 84 mg group compared with the placebo group. Analysis was by intention to treat. Safety was assessed in all patients who received at least one dose of experimental treatment. This trial is registered with ClinicalTrials.gov, number NCT02240030. FINDINGS: Between Dec 4, 2014, and Aug 26, 2016, 351 patients were enrolled and randomly assigned to receive CVT-301 60 mg (115 patients), CVT-301 84 mg (120 patients), or placebo (116 patients). Of these, 339 received the assigned study treatment (CVT-301 60 mg, n=113; CVT-301 84 mg, n=114; placebo, n=112) and 290 completed the study (CVT-301 60 mg, n=96; CVT-301 84 mg, n=97; placebo, n=97). The least-squares mean difference in UPDRS motor score change from predose to 30 min postdose was -5·91 (SE 1·50, 95% CI -8·86 to -2·96) for the placebo group and -9·83 (1·51; -12·79 to -6·87) for the CVT-301 84 mg group (between-group difference -3·92 [-6·84 to -1·00]; p=0·0088). Treatments were safe and well tolerated. Severe adverse events were reported by 2 (2%) of 112 patients in the placebo group, 7 (6%) of 113 in the CVT-301 60 mg group, and 5 (4%) of 114 in the CVT-301 84 mg group, with no severe adverse event occurring in more than one patient in any treatment group. 11 (3%) of 339 patients had 19 serious adverse events (three [3%] of 112 patients in placebo, six [5%] of 113 in CVT-301 60 mg, and two [2%] of 114 in CVT-301 84 mg). Of these, hypotension and atrial fibrillation were assessed by investigators to be possibly related to the study drug. INTERPRETATION: CVT-301 can improve UPDRS motor scores of patients with Parkinson's disease during in-clinic off periods, with few severe or serious adverse events. The long-term safety and efficacy of CVT-301 need to be investigated in future studies. FUNDING: Acorda Therapeutics.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019. PMID: 30663606. doi:10.1016/S1474-4422(18)30405-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。